Zymeworks Inc. (ZYME)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 39 | 27 | 412 | 76 | 76 | 106 | 37 | - |
| Operating profit | $m | -93 | -156 | ||||||
| Net profit | $m | -181 | -212 | 124 | -119 | -123 | -81 | -150 | 98 |
| EPS reported | $ | -1.08 | -2.02 | ||||||
| Operating cashflow per share | $ | -0.44 | -1.63 | ||||||
| Capex per share | $ | 0.02 | 0.02 | ||||||
| FCF per share | $ | -0.46 | -1.65 | ||||||
| Free cash flow | $m | -35 | -120 | ||||||
| Net debt | $m | -229 | -16,009 | ||||||
| Book value equity | $m | 269 | 80 | ||||||
| Book value per share | $ | 3.56 | 1.10 | ||||||
| Number of shares | m | 75.34 | 72.99 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 7.39 | 24.68 | ||||||
| P/S LTM | x | 18.72 | 53.43 | ||||||
| P/FCF LTM | x | -57.45 | -16.52 | ||||||
| EV/EBITDA LTM | x | -28.56 | -14.01 | ||||||
| EV/Sales LTM | x | 18.50 | -4,354.01 | ||||||
| Earnings Yield LTM | % | -4.09% | -8.62% | ||||||
| FCF Yield | % | -1.74% | -6.05% | ||||||
| Quality | |||||||||
| ROE | % | -30.22% | -0.74% | ||||||
| ROIC | % | -30.08% | -0.04% | ||||||
| Operating margin | % | -87.33% | -4.19% | ||||||
| Gross margin | % | +100.00% | +87.78% | ||||||
| FCF/Sales | % | -32.58% | -323.90% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +38.87% | -51.34% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -1.89 | -0.45 | ||||||
| Net Debt/EBITDA | x | 0.33 | 1,167.77 | ||||||
| EBIT/Net interest | x | 0.00 | -75.30 | ||||||
| Net debt/market cap | % | 0.00% | +9.12% | ||||||
| Net debt/Equity | x | -0.85 | -199.19 | ||||||
| Gross debt/equity | x | 0.07 | 3.34 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Zymeworks Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying, advancing, and bringing to market biological therapies aimed at combating cancer. Its pipeline features two primary experimental treatments: zanidatamab, a cutting-edge bispecific antibody currently undergoing Phase 1 and Phase 2 studies for various malignancies such as those affecting the biliary tract, gastroesophageal region (adenocarcinomas), breast, and colon; and ZW49, an antibody-drug conjugate targeting two sites on the human epidermal growth factor receptor 2 (HER2), which is in Phase 1 trials for advanced or spreading tumors that express HER2. Zymeworks maintains significant alliances with several pharmaceutical leaders, including Merck Sharp & Dohme Research Ltd., Eli Lilly and Company, Bristol-Myers Squibb company, GlaxoSmithKline Intellectual Property Development Ltd., Daiichi Sankyo Co., Ltd., Janssen Biotech, Inc., BeiGene, Ltd., and Exelixis, Inc. Furthermore, it engages in cooperative research and licensing agreements with LEO Pharma A/S, specifically for the exploration, advancement, and market introduction of bispecific antibodies, and with Iconic Therapeutics, Inc. Established in 2003, Zymeworks Inc. operates from its headquarters located in Vancouver, Canada.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Zymeworks Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying, advancing, and bringing to market biological therapies aimed at combating cancer. Its pipeline features two primary experimental treatments: zanidatamab, a cutting-edge bispecific antibody currently undergoing Phase 1 and Phase 2 studies for various malignancies such as those affecting the biliary tract, gastroesophageal region (adenocarcinomas), breast, and colon; and ZW49, an antibody-drug conjugate targeting two sites on the human epidermal growth factor receptor 2 (HER2), which is in Phase 1 trials for advanced or spreading tumors that express HER2. Zymeworks maintains significant alliances with several pharmaceutical leaders, including Merck Sharp & Dohme Research Ltd., Eli Lilly and Company, Bristol-Myers Squibb company, GlaxoSmithKline Intellectual Property Development Ltd., Daiichi Sankyo Co., Ltd., Janssen Biotech, Inc., BeiGene, Ltd., and Exelixis, Inc. Furthermore, it engages in cooperative research and licensing agreements with LEO Pharma A/S, specifically for the exploration, advancement, and market introduction of bispecific antibodies, and with Iconic Therapeutics, Inc. Established in 2003, Zymeworks Inc. operates from its headquarters located in Vancouver, Canada.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free